Document is current
Any future updates will be listed below
-
Authors
Bacharaki, Dimitra
Karagiannis, Minas
Giannakopoulos, Panagiotis
Papachristou, Evangelos
Divanis, Dimitrios
Sardeli, Aggeliki
Petrou, Dimitra
Nikolopoulos, Petros
Bratsiakou, Adamantia
Zoi, Vassiliki
Piliouras, Nikitas
Damoraki, Georgia
Liakopoulos, Vassilios
Goumenos, Dimitrios
Giamarellos-Bourboulis, Evangelos J.
-
Funding
Funding for this research was provided by:
Hellenic Institute for the Study of Sepsis
- License Information
-
More Information
Article History
Received: 20 February 2023
Accepted: 28 August 2023
First Online: 6 September 2023
Declarations
:
: The study protocol and informed consent form were approved by the Institutional Review Boards of the three participating centers: Scientific Council of University General Hospital Attikon (approval 48/24.02.202), Scientific Council of University General Hospital of Patras (approval 161/01.04.2021) and Scientific Council of AHEPA University General Hospital of Thessaloniki (199/30.3.2021). All patients were enrolled in the study after providing written informed consent.
: Not applicable.
: EG-B has received honoraria from Abbott Products Operations AG, bioMérieux, Brahms GmbH, GSK, InflaRx GmbH, Sobi AB and XBiotech Inc; independent educational grants from Abbott Products Operations, AbbVie, bioMérieux Inc, InflaRx GmbH, Johnson & Johnson, MSD, Novartis, Sobi AB, UCB and XBiotech Inc.; and funding from the Horizon2020 Marie-Curie Project European Sepsis Academy (granted to the National and Kapodistrian University of Athens), the Horizon 2020 European Grants ImmunoSep and RISKinCOVID (granted to the Hellenic Institute for the Study of Sepsis) and from the Horizon Europe project EPIC-CROWN-2 (granted to the Hellenic Institute for the Study of Sepsis).The other authors do not have any conflict to disclose.
